Japan price cuts loom less
This article was originally published in The Gray Sheet
Executive Summary
AdvaMed is "cautiously optimistic" that upcoming biannual cuts in reimbursement for medical devices in Japan will be in aggregate less severe than in the past, the trade group's CEO Steve Ubl said. Japan's MHLW has already released its proposal to manufacturers, who have the opportunity to raise objections. The final reimbursement levels, which take effect April 1, are expected to be released shortly. The device industry continues to lobby against Japan's use of foreign average pricing and other measures to reduce device payments (1"The Gray Sheet" Oct. 8, 2007, p. 3)
You may also be interested in...
Japan’s Device Payments Will Continue To Decline, Government Official Says
Pressures on reimbursement in Japan will not ease anytime soon and more payment cuts for medical devices are expected in 2008, according to a top Japanese health official
Japan Grants Global-First Approval To Zolbetuximab, 15 Other New Drugs
Astellas's first-in class CLDN18.2-targeting antibody receives its first approval worldwide, while crovalimab and a number of drugs for rare diseases also receive nods from regulators and are now awaiting reimbursement price-listing.
Hanmi-OCI Merger Hits Wall As Brothers Win Shareholder Vote, Board Seats
The planned merger of Korea's Hanmi Pharm Group with OCI Group hits a major speed bump as the two sons of Hanmi's founder and other candidates recommended by them secture board seats. But it remains to be seen how the Lim brothers will fulfil their ambitious promises.